WO2017094722A1 - タンパク質溶液を製造する方法 - Google Patents
タンパク質溶液を製造する方法 Download PDFInfo
- Publication number
- WO2017094722A1 WO2017094722A1 PCT/JP2016/085409 JP2016085409W WO2017094722A1 WO 2017094722 A1 WO2017094722 A1 WO 2017094722A1 JP 2016085409 W JP2016085409 W JP 2016085409W WO 2017094722 A1 WO2017094722 A1 WO 2017094722A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- polar solvent
- amino acid
- solution
- acid sequence
- Prior art date
Links
- 239000012460 protein solution Substances 0.000 title claims abstract description 72
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 160
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 143
- 239000002798 polar solvent Substances 0.000 claims abstract description 58
- 239000006185 dispersion Substances 0.000 claims abstract description 52
- 108010022355 Fibroins Proteins 0.000 claims description 58
- 229920001872 Spider silk Polymers 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 101710172711 Structural protein Proteins 0.000 claims description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000010438 heat treatment Methods 0.000 claims description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 8
- 241000256856 Vespidae Species 0.000 claims description 6
- 102000011782 Keratins Human genes 0.000 claims description 4
- 108010076876 Keratins Proteins 0.000 claims description 4
- VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 claims description 4
- 230000001172 regenerating effect Effects 0.000 claims description 3
- 238000003825 pressing Methods 0.000 abstract description 12
- 235000018102 proteins Nutrition 0.000 description 116
- 150000001413 amino acids Chemical group 0.000 description 74
- 229920001184 polypeptide Polymers 0.000 description 55
- 108090000765 processed proteins & peptides Proteins 0.000 description 55
- 102000004196 processed proteins & peptides Human genes 0.000 description 55
- 239000000243 solution Substances 0.000 description 32
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 238000000502 dialysis Methods 0.000 description 12
- 241000239290 Araneae Species 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 239000008176 lyophilized powder Substances 0.000 description 7
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 101150082901 ADF3 gene Proteins 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 101710112083 Para-Rep C1 Proteins 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 102100022881 Rab proteins geranylgeranyltransferase component A 1 Human genes 0.000 description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 6
- 108091081024 Start codon Proteins 0.000 description 6
- 101710119887 Trans-acting factor B Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 230000003252 repetitive effect Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 241000255789 Bombyx mori Species 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- 101000708578 Milk vetch dwarf virus (isolate N) Para-Rep C3 Proteins 0.000 description 5
- 206010036790 Productive cough Diseases 0.000 description 5
- 108010013296 Sericins Proteins 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000003802 sputum Anatomy 0.000 description 5
- 208000024794 sputum Diseases 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000007922 dissolution test Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 238000010191 image analysis Methods 0.000 description 4
- 229910017053 inorganic salt Inorganic materials 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- -1 oxoacid ion Chemical class 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108010091324 3C proteases Proteins 0.000 description 3
- 101150003973 ADF4 gene Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000430519 Human rhinovirus sp. Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000011218 seed culture Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical group FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 239000002879 Lewis base Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101710084218 Master replication protein Proteins 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 241000238902 Nephila clavipes Species 0.000 description 2
- 101710112078 Para-Rep C2 Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102100022880 Rab proteins geranylgeranyltransferase component A 2 Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
- 101710119961 Trans-acting factor C Proteins 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- IWOUKMZUPDVPGQ-UHFFFAOYSA-N barium nitrate Chemical compound [Ba+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O IWOUKMZUPDVPGQ-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 150000007527 lewis bases Chemical class 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- IIPYXGDZVMZOAP-UHFFFAOYSA-N lithium nitrate Chemical compound [Li+].[O-][N+]([O-])=O IIPYXGDZVMZOAP-UHFFFAOYSA-N 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 2
- 238000005312 nonlinear dynamic Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000013587 production medium Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 210000005070 sphincter Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- DHEQXMRUPNDRPG-UHFFFAOYSA-N strontium nitrate Chemical compound [Sr+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O DHEQXMRUPNDRPG-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 description 2
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 1
- ALWXETURCOIGIZ-UHFFFAOYSA-N 1-nitropropylbenzene Chemical compound CCC([N+]([O-])=O)C1=CC=CC=C1 ALWXETURCOIGIZ-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000193935 Araneus diadematus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- UNMYWSMUMWPJLR-UHFFFAOYSA-L Calcium iodide Chemical compound [Ca+2].[I-].[I-] UNMYWSMUMWPJLR-UHFFFAOYSA-L 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 101710197767 Fibroin heavy chain Proteins 0.000 description 1
- MPCRDALPQLDDFX-UHFFFAOYSA-L Magnesium perchlorate Chemical compound [Mg+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O MPCRDALPQLDDFX-UHFFFAOYSA-L 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 241000238903 Nephila Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- CECABOMBVQNBEC-UHFFFAOYSA-K aluminium iodide Chemical compound I[Al](I)I CECABOMBVQNBEC-UHFFFAOYSA-K 0.000 description 1
- ZRGUXTGDSGGHLR-UHFFFAOYSA-K aluminum;triperchlorate Chemical compound [Al+3].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O ZRGUXTGDSGGHLR-UHFFFAOYSA-K 0.000 description 1
- QJLDTVCWUDCBME-UHFFFAOYSA-K aluminum;trithiocyanate Chemical compound [Al+3].[S-]C#N.[S-]C#N.[S-]C#N QJLDTVCWUDCBME-UHFFFAOYSA-K 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- NKQIMNKPSDEDMO-UHFFFAOYSA-L barium bromide Chemical compound [Br-].[Br-].[Ba+2] NKQIMNKPSDEDMO-UHFFFAOYSA-L 0.000 description 1
- 229910001620 barium bromide Inorganic materials 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- SGUXGJPBTNFBAD-UHFFFAOYSA-L barium iodide Chemical compound [I-].[I-].[Ba+2] SGUXGJPBTNFBAD-UHFFFAOYSA-L 0.000 description 1
- 229910001638 barium iodide Inorganic materials 0.000 description 1
- 229940075444 barium iodide Drugs 0.000 description 1
- OOULUYZFLXDWDQ-UHFFFAOYSA-L barium perchlorate Chemical compound [Ba+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O OOULUYZFLXDWDQ-UHFFFAOYSA-L 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229910001622 calcium bromide Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 description 1
- 229910001640 calcium iodide Inorganic materials 0.000 description 1
- 229940046413 calcium iodide Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001793 charged compounds Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003484 crystal nucleating agent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- CAIVQSJDQAHOHT-UHFFFAOYSA-L dipotassium;dithiocyanate Chemical compound [K+].[K+].[S-]C#N.[S-]C#N CAIVQSJDQAHOHT-UHFFFAOYSA-L 0.000 description 1
- AXZAYXJCENRGIM-UHFFFAOYSA-J dipotassium;tetrabromoplatinum(2-) Chemical compound [K+].[K+].[Br-].[Br-].[Br-].[Br-].[Pt+2] AXZAYXJCENRGIM-UHFFFAOYSA-J 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- MVFCKEFYUDZOCX-UHFFFAOYSA-N iron(2+);dinitrate Chemical compound [Fe+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MVFCKEFYUDZOCX-UHFFFAOYSA-N 0.000 description 1
- DXTCFKRAUYBHRC-UHFFFAOYSA-L iron(2+);dithiocyanate Chemical compound [Fe+2].[S-]C#N.[S-]C#N DXTCFKRAUYBHRC-UHFFFAOYSA-L 0.000 description 1
- LHOWRPZTCLUDOI-UHFFFAOYSA-K iron(3+);triperchlorate Chemical compound [Fe+3].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O LHOWRPZTCLUDOI-UHFFFAOYSA-K 0.000 description 1
- GYCHYNMREWYSKH-UHFFFAOYSA-L iron(ii) bromide Chemical compound [Fe+2].[Br-].[Br-] GYCHYNMREWYSKH-UHFFFAOYSA-L 0.000 description 1
- BQZGVMWPHXIKEQ-UHFFFAOYSA-L iron(ii) iodide Chemical compound [Fe+2].[I-].[I-] BQZGVMWPHXIKEQ-UHFFFAOYSA-L 0.000 description 1
- MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 1
- 229910001486 lithium perchlorate Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- ZJZXSOKJEJFHCP-UHFFFAOYSA-M lithium;thiocyanate Chemical compound [Li+].[S-]C#N ZJZXSOKJEJFHCP-UHFFFAOYSA-M 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- BLQJIBCZHWBKSL-UHFFFAOYSA-L magnesium iodide Chemical compound [Mg+2].[I-].[I-] BLQJIBCZHWBKSL-UHFFFAOYSA-L 0.000 description 1
- 229910001641 magnesium iodide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- SXTGAOTXVOMSFW-UHFFFAOYSA-L magnesium;dithiocyanate Chemical compound [Mg+2].[S-]C#N.[S-]C#N SXTGAOTXVOMSFW-UHFFFAOYSA-L 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N methyl monoether Natural products COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Chemical compound [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 229910001487 potassium perchlorate Inorganic materials 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- YJPVTCSBVRMESK-UHFFFAOYSA-L strontium bromide Chemical compound [Br-].[Br-].[Sr+2] YJPVTCSBVRMESK-UHFFFAOYSA-L 0.000 description 1
- 229910001625 strontium bromide Inorganic materials 0.000 description 1
- 229940074155 strontium bromide Drugs 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- KRIJWFBRWPCESA-UHFFFAOYSA-L strontium iodide Chemical compound [Sr+2].[I-].[I-] KRIJWFBRWPCESA-UHFFFAOYSA-L 0.000 description 1
- 229910001643 strontium iodide Inorganic materials 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- MXRFIUHRIOLIIV-UHFFFAOYSA-L strontium;diperchlorate Chemical compound [Sr+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O MXRFIUHRIOLIIV-UHFFFAOYSA-L 0.000 description 1
- YNQRWDDCTKWYJP-UHFFFAOYSA-L strontium;dithiocyanate Chemical compound [Sr+2].[S-]C#N.[S-]C#N YNQRWDDCTKWYJP-UHFFFAOYSA-L 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- PUGUQINMNYINPK-UHFFFAOYSA-N tert-butyl 4-(2-chloroacetyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(C(=O)CCl)CC1 PUGUQINMNYINPK-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- RXBXBWBHKPGHIB-UHFFFAOYSA-L zinc;diperchlorate Chemical compound [Zn+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O RXBXBWBHKPGHIB-UHFFFAOYSA-L 0.000 description 1
- MLVWCBYTEFCFSG-UHFFFAOYSA-L zinc;dithiocyanate Chemical compound [Zn+2].[S-]C#N.[S-]C#N MLVWCBYTEFCFSG-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L89/00—Compositions of proteins; Compositions of derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43586—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from silkworms
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2389/00—Characterised by the use of proteins; Derivatives thereof
Definitions
- the present invention relates to a method for producing a protein solution.
- the present invention also relates to a method for producing a molded body using a protein solution.
- structural proteins are generally hydrophobic polymers and have poor solubility in polar solvents such as water. It may be possible to obtain a concentrated protein solution by distilling the solvent from the dilute solution of the structural protein, but this operation causes protein denaturation, gelation, decomposition, etc., leading to a decrease in yield. sell.
- Patent Document 1 discloses a method for concentrating a protein aqueous solution, wherein the protein aqueous solution is brought into contact with a polyether polymer or polyol polymer aqueous solution through a dialysis membrane. Has been proposed.
- the main object of the present invention is to provide a method capable of easily obtaining a high concentration protein solution without requiring dialysis or the like.
- the present inventors can obtain a protein solution under milder conditions while suppressing protein alteration and the like by preparing a solution under pressure. Based on this finding, the present invention has been completed.
- One aspect of the present invention is to apply a pressure to a dispersion containing a protein and a polar solvent in which the protein is dispersed to obtain a protein solution containing the protein and a polar solvent in which the protein is dissolved.
- a method for producing a protein solution is to apply a pressure to a dispersion containing a protein and a polar solvent in which the protein is dispersed to obtain a protein solution containing the protein and a polar solvent in which the protein is dissolved.
- a high-concentration protein solution can be easily obtained without going through steps such as dialysis.
- a protein solution containing spider silk fibroin and a polar solvent in which the spider silk fibroin is dissolved and the concentration of the spider silk fibroin dissolved in the polar solvent is based on the mass of the protein solution.
- a protein solution of 15 to 70% by mass can be obtained.
- Another aspect of the present invention is to obtain a protein solution containing a protein and a polar solvent in which the protein is dissolved by the above method, and removing the polar solvent from the protein solution to obtain a molded article containing the protein. And providing a method for producing a molded body.
- a protein compact can be easily produced using a high-concentration protein solution.
- Still another aspect of the present invention is to obtain a protein solution containing a protein and a polar solvent in which the protein is dissolved by applying pressure to the polar solvent in contact with the molded article containing the protein. Recovering the protein from the shaped body, comprising recovering the protein from the protein solution.
- Example 4 is a photograph showing the analysis results of the protein solution obtained in Example 4 by SDS-PAGE.
- 6 is a photograph showing the analysis result of the protein solution obtained in Example 5 by SDS-PAGE.
- 2 is a photograph showing the results of SDS-PAGE analysis of the protein solutions obtained in Examples 14 to 19.
- One embodiment of a method for producing a protein solution comprises preparing a dispersion containing protein and a polar solvent in which the protein is dispersed, and applying pressure to the dispersion to dissolve the protein and the protein. Obtaining a protein solution containing a polar solvent.
- the dispersion containing protein can be prepared by mixing protein in powder form or any other form with a polar solvent. It is not always necessary that the total amount of the protein contained in the dispersion is dispersed in the polar solvent, and a part of the protein may be dissolved in the polar solvent.
- the polar solvent used for preparing the dispersion is, for example, one or more solvents selected from the group consisting of water, alcohol, dimethyl sulfoxide (DMSO), dimethylformamide (DMF) and hexafluoroacetone (HFA). May be included.
- the polar solvent can be dimethyl sulfoxide alone or a mixed solvent of dimethyl sulfoxide and water.
- the polar solvent can be water.
- the polar solvent may contain an alcohol.
- the polar solvent may be a mixed solvent of water and alcohol, a mixed solvent of dimethyl sulfoxide and alcohol, or a mixed solvent of water, alcohol and dimethyl sulfoxide.
- the ratio of alcohol to the total amount of polar solvent (or mixed solvent) may be 5 to 100% by mass, or 10 to 50% by mass.
- alcohol means a compound comprising an aliphatic group which may have a substituent and a hydroxyl group bonded to the aliphatic group.
- the aliphatic group may be substituted with a halogen atom such as a fluorine atom, or may be unsubstituted.
- a fluoroalcohol having an aliphatic group substituted with a fluorine atom is hexafluoroisopropanol (HFIP).
- An alcohol having a low boiling point is particularly advantageous in that the conditions such as preparation of an alcohol solution and its concentration, formation of a molded article, etc. can be mild.
- the boiling point of the alcohol may be, for example, 99 ° C. or lower and 50 ° C. or higher under 1 atmosphere.
- the boiling point of the alcohol may be 60 ° C. or higher under 1 atmosphere.
- an alcohol having one hydroxyl group tends to have a lower boiling point than an alcohol having two or more hydroxyl groups.
- the carbon number of the alcohol is not particularly limited, but may be 1 to 10. In particular, from the viewpoint of obtaining a protein solution under mild conditions, the carbon number of the alcohol may be 2 to 8 or 2 to 5.
- the alcohol contained in the polar solvent is, for example, one or more carbons selected from the group consisting of methanol, ethanol, propanol, butanol, pentanol, hexanol, heptanol, octanol, nonanol, decanol, and isomers of these alcohols.
- It may be an alcohol having a number of 1 to 10, or may be one or more alcohols having 2 to 5 carbon atoms selected from the group consisting of ethanol, propanol, butanol, and isomers of these alcohols. It may be one or more alcohols selected from the group consisting of 1-propanol, and 2-propanol.
- the protein may be a structural protein.
- the structural protein means a protein that forms or maintains a structure, a form, or the like in a living body.
- Structural proteins include hydrophobic proteins and polypeptides that tend to undergo self-aggregation in polar solvents. Since these structural proteins generally have low solubility in polar solvents, the method of this embodiment is particularly useful for producing a solution of these structural proteins.
- the structural protein may include one or more selected from the group consisting of fibroin and keratin.
- the fibroin may be, for example, one or more selected from the group consisting of silk fibroin, spider silk fibroin, and hornet silk fibroin.
- the structural protein may be silk fibroin, spider silk fibroin or a combination thereof. When silk fibroin and spider silk fibroin are used in combination, the ratio of silk fibroin may be, for example, 40 parts by mass or less, 30 parts by mass or less, or 10 parts by mass or less with respect to 100 parts by mass of spider silk fibroin. .
- Silk is a fiber obtained from cocoons made by silkworms, Bombyx mori larvae.
- one silk thread is composed of two silk fibroins and glue quality (sericin) covering them from the outside.
- Silk fibroin is composed of many fibrils.
- Silk fibroin is covered with 4 layers of sericin.
- silk filaments obtained by dissolving and removing outer sericin by refining are used for clothing.
- General silk has a specific gravity of 1.33, an average fineness of 3.3 decitex, and a fiber length of about 1300 to 1500 m.
- Silk fibroin can be obtained from natural or domestic silkworms, or used or discarded silk fabrics.
- the silk fibroin may be sericin-removed silk fibroin, sericin-unremoved silk fibroin, or a combination thereof.
- the sericin-removed silk fibroin is a powder obtained by freeze-drying silk fibroin purified by removing sericin covering the silk fibroin and other fats.
- Sericin-unremoved silk fibroin is an unpurified fibroin from which sericin and the like have not been removed.
- the spider silk fibroin may contain a spider silk polypeptide selected from the group consisting of a natural spider silk protein and a polypeptide derived from the natural spider silk protein.
- spider silk proteins examples include large sphincter bookmark protein, weft protein, and small bottle-like gland protein. Since the large splint bookmarker has a repetitive region composed of a crystal region and an amorphous region, it is presumed to have both high stress and stretchability. A great feature of spider silk wefts is that they have no crystal regions but have repeating regions consisting of amorphous regions. On the other hand, the weft yarn is inferior in stress to the large spout tube bookmark yarn, but has high stretchability. This is considered to be because most of the weft is composed of amorphous regions.
- the large sputum bookmark thread protein is produced in spider large bottle-like glands and has the characteristic of excellent toughness.
- Examples of the large sphincter bookmark thread protein include large bottle-shaped gland spiders MaSp1 and MaSp2 derived from Nephila clavipes, and ADF3 and ADF4 derived from two spider spiders (Araneus diadematus).
- ADF3 is one of the two main dragline proteins of the elder spider.
- Polypeptides derived from natural spider silk proteins may be polypeptides derived from these bookmark silk proteins.
- a polypeptide derived from ADF3 is relatively easy to synthesize and has excellent properties in terms of strength and toughness.
- weft protein is produced in the flagellate gland of spiders.
- flagellum silk protein derived from the American spider (Nephila clavipes) can be mentioned.
- the polypeptide derived from the natural spider silk protein may be a recombinant spider silk protein.
- recombinant spider silk proteins include mutants, analogs or derivatives of natural spider silk proteins.
- a preferred example of such a polypeptide is a recombinant spider silk protein (also referred to as “polypeptide derived from a large sputum bookmarker protein”).
- a polypeptide derived from a large sputum dragline protein may contain 2 or more, 5 or more, or 10 or more amino acid sequence units (also referred to as motifs) represented by Formula 1: REP1-REP2 (1). Good.
- the upper limit of the number of units of the amino acid sequence represented by Formula 1: REP1-REP2 (1) is not particularly limited, but may be, for example, 300 or less, or 200 or less.
- a polypeptide derived from a large sputum dragline protein includes a unit of an amino acid sequence represented by Formula 1: REP1-REP2 (1), and a C-terminal sequence is represented by any one of SEQ ID NOs: 1 to 3.
- polypeptide that is an amino acid sequence having 90% or more homology with the amino acid sequence shown in any one of SEQ ID NOs: 1 to 3.
- the unit of the amino acid sequence represented by Formula 1: REP1-REP2 (1) may be the same or different.
- the ratio of the number of alanine residues to the total number of amino acid residues in the REP1 motif is usually 83% or more, and may be 86% or more, 90% or more, or 95% or more.
- REP1 may be polyalanine in which the ratio of the number of alanine residues is 100%. 2 or more, 3 or more, 4 or more, or 5 or more may be sufficient as the alanine (Ala) which is located in a row in REP1.
- alanine arranged continuously may be 20 residues or less, 16 residues or less, 12 residues or less, or 10 residues or less.
- the REP1 motif may contain other amino acid residues selected from serine (Ser), glycine (Gly), glutamine (Gln) and the like in addition to alanine (Ala).
- REP2 is an amino acid sequence consisting of 10 to 200 amino acids, and is the total residue of glycine (Gly), serine (Ser), glutamine (Gln) and alanine (Ala) contained in the amino acid sequence
- the number may be 40% or more, 60% or more, or 70% or more with respect to the total number of amino acid residues.
- REP1 corresponds to a crystalline region that forms a crystalline ⁇ -sheet within the fiber
- REP2 is an amorphous region that is more flexible within the fiber and largely lacks a regular structure.
- [REP1-REP2] corresponds to a repetitive region (repetitive sequence) composed of a crystal region and an amorphous region, and is a characteristic sequence of a bookmark thread protein.
- the amino acid sequence shown in SEQ ID NO: 1 is identical to the amino acid sequence consisting of the 50-residue amino acid at the C-terminal of the amino acid sequence of ADF3 (NCBI accession number: AAC47010, GI: 1263287).
- the amino acid sequence shown in SEQ ID NO: 2 is identical to the amino acid sequence obtained by removing 20 residues from the C-terminus of the amino acid sequence shown in SEQ ID NO: 1.
- the amino acid sequence shown in SEQ ID NO: 3 is identical to the amino acid sequence obtained by removing 29 residues from the C-terminus of the amino acid sequence shown in SEQ ID NO: 1.
- the polypeptide comprising two or more units of the amino acid sequence represented by Formula 1: REP1-REP2 (1) can be, for example, a polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 7.
- the polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 7 is an amino acid sequence of ADF3 in which an amino acid sequence (SEQ ID NO: 4) consisting of a start codon, His10 tag and HRV3C protease (Human rhinovirus 3C protease) recognition site is added to the N-terminus ( NCBI accession number: AAC47010, GI: 1263287), and the mutation is mutated to terminate at the 543rd amino acid residue.
- Formula 1 In a polypeptide comprising two or more amino acid sequence units represented by REP1-REP2 (1), one or more amino acids in the amino acid sequence represented by SEQ ID NO: 7 are substituted, deleted, inserted and / or added. And a protein having a repetitive region consisting of a crystalline region and an amorphous region.
- “one or more” means, for example, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10 And a range selected from one or several.
- “1 or several” means 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to Two or one is meant.
- the polypeptide containing two or more units of the amino acid sequence represented by Formula 1: REP1-REP2 (1) may be a recombinant protein derived from ADF4 having the amino acid sequence represented by SEQ ID NO: 8.
- the amino acid sequence shown in SEQ ID NO: 8 comprises a start codon, His10 tag and HRV3C protease (Human) at the N-terminus of the partial amino acid sequence of ADF4 (NCBI accession numbers: AAC47011, GI: 1263289) obtained from the NCBI database.
- Amino acid sequence (SEQ ID NO: 4) consisting of a rhinovirus 3C protease) recognition site is added.
- Formula 1 In the polypeptide comprising two or more amino acid sequence units represented by REP1-REP2 (1), one or more amino acids in the amino acid sequence represented by SEQ ID NO: 8 are substituted, deleted, inserted and / or added. And a polypeptide having a repetitive region consisting of a crystalline region and an amorphous region.
- the polypeptide comprising two or more units of the amino acid sequence represented by Formula 1: REP1-REP2 (1) may be a MaSp2-derived recombinant protein having the amino acid sequence represented by SEQ ID NO: 9.
- the amino acid sequence shown in SEQ ID NO: 9 consists of a partial sequence of MaSp2 obtained from the NCBI database (NCBI accession number: AAT75313, GI: 50363147) at the N-terminus with a start codon, His10 tag and HRV3C protease (Human rhinovirus).
- 3C protease) amino acid sequence consisting of a recognition site (SEQ ID NO: 4) is added.
- Formula 1 A polypeptide comprising two or more units of the amino acid sequence represented by REP1-REP2 (1) is substituted, deleted, inserted and / or added with one or more amino acids in the amino acid sequence represented by SEQ ID NO: 9 And a polypeptide having a repetitive region consisting of a crystalline region and an amorphous region.
- the polypeptide derived from the weft protein may contain 10 or more, 20 or more, or 30 or more units of the amino acid sequence represented by Formula 2: REP3 (2).
- the upper limit of the number of units of the amino acid sequence represented by Formula 2: REP3 (2) is not particularly limited, but may be, for example, 300 or less, or 200 or less.
- REP3 means an amino acid sequence composed of Gly-Pro-Gly-Gly-X, and X is a group consisting of alanine (Ala), serine (Ser), tyrosine (Tyr) and valine (Val). It means one amino acid selected.
- a polypeptide comprising 10 or more units of the amino acid sequence represented by REP3 (2) is, for example, a recombinant protein derived from flagellar silk protein having the amino acid sequence represented by SEQ ID NO: 10. it can.
- the amino acid sequence shown in SEQ ID NO: 10 is an N corresponding to a repeat part and a motif of a partial sequence of flagellar silk protein of American spider spider (NCBI accession numbers: AAF36090, GI: 7106224) obtained from the NCBI database.
- PR1 sequence Amino acid sequence from the 1220th residue to the 1659th residue from the end (referred to as PR1 sequence), and a partial sequence of American yellow spider flagellar silk protein obtained from the NCBI database (NCBI accession number: AAC38847, GI: 2833649) ) From the C-terminal to the 816th to 907th residues from the C-terminal, and an amino acid sequence comprising a start codon, His10 tag and HRV3C protease recognition site at the N-terminal of the combined sequence (SEQ ID NO: 4) The It is an addition to the amino acid sequence.
- Formula 2 In the polypeptide comprising 10 or more units of the amino acid sequence represented by REP3 (2), one or more amino acids are substituted, deleted, inserted and / or added in the amino acid sequence represented by SEQ ID NO: 10 It can be a polypeptide having a repeating region consisting of an amino acid sequence and consisting of an amorphous region.
- the molecular weight of the protein or polypeptide may be 500 kDa or less, 300 kDa or less, 200 kDa or less, or 100 kDa or less, or 10 kDa or more, from the viewpoint of productivity when producing recombinant protein using microorganisms such as E. coli as hosts. May be.
- Hornet silk fibroin is a protein produced by bee larvae and may contain a polypeptide selected from the group consisting of a natural hornet silk protein and a polypeptide derived from the natural hornet silk protein.
- the polypeptide can be produced, for example, using a host transformed with an expression vector containing a gene encoding the polypeptide.
- the method for producing a gene encoding a polypeptide is not particularly limited.
- the gene in the case of a natural spider silk protein, the gene can be produced by a method of amplifying and cloning a gene encoding the protein from a spider-derived cell by polymerase chain reaction (PCR) or the like, or by chemical synthesis. .
- the method of chemical synthesis of the gene is not particularly limited.
- AKTA oligopilot plus 10/100 GE Healthcare Japan Co., Ltd.
- a gene can be chemically synthesized by a method of linking oligonucleotides automatically synthesized by a company) by PCR or the like.
- a gene encoding a protein consisting of an amino acid sequence in which an amino acid sequence consisting of a start codon and a His10 tag is added to the N-terminus of the above amino acid sequence may be synthesized. Good.
- a plasmid, phage, virus or the like capable of expressing a protein from a DNA sequence
- the plasmid type expression vector is not particularly limited as long as it can express the target gene in the host cell and can amplify itself.
- E. coli Rosetta (DE3) E. coli Rosetta
- a pET22b (+) plasmid vector, a pCold plasmid vector, or the like can be used.
- pET22b (+) plasmid vector can be used from the viewpoint of protein productivity.
- the host for example, animal cells, plant cells, microorganisms and the like can be used.
- a dispersion and a protein solution obtained therefrom may contain a combination of the above-mentioned structural proteins such as silk fibroin and spider silk fibroin and other proteins.
- structural proteins such as silk fibroin and spider silk fibroin and other proteins.
- other proteins include collagen, soy protein, casein, keratin, and whey protein.
- the proportion of other proteins may be, for example, 40 parts by mass or less, 30 parts by mass or less, or 10 parts by mass or less with respect to 100 parts by mass of the structural protein.
- the concentration of protein in the dispersion can be 1% by mass or more, 15% by mass or more, 30% by mass or more, 40% by mass or more, or 50% by mass or more based on the mass of the dispersion. From the viewpoint of the production efficiency of the protein solution, the concentration of the protein can be 70% by mass or less, 65% by mass or less, or 60% by mass or less based on the mass of the dispersion or protein solution.
- the dispersion may further contain one or more inorganic salts.
- an inorganic salt By adding an inorganic salt to the dispersion, the effect of improving the solubility due to pressurization can be made even more remarkable.
- the inorganic salt include inorganic salts composed of the following Lewis acid and Lewis base.
- the Lewis base may be, for example, an oxoacid ion (nitrate ion, perchlorate ion, etc.), a metal oxoacid ion (permanganate ion, etc.), a halide ion, thiocyanate ion, cyanate ion, or the like.
- the Lewis acid may be, for example, metal ions such as alkali metal ions and alkaline earth metal ions, polyatomic ions such as ammonium ions, complex ions, and the like.
- inorganic salts include lithium salts such as lithium chloride, lithium bromide, lithium iodide, lithium nitrate, lithium perchlorate, and lithium thiocyanate, calcium chloride, calcium bromide, calcium iodide, calcium nitrate.
- Calcium salts such as calcium perchlorate and calcium thiocyanate, iron salts such as iron chloride, iron bromide, iron iodide, iron nitrate, iron perchlorate and iron thiocyanate, and aluminum chloride, Aluminum salts such as aluminum bromide, aluminum iodide, aluminum nitrate, aluminum perchlorate, and aluminum thiocyanate, such as potassium chloride, potassium bromide, potassium iodide, potassium nitrate, potassium perchlorate, and potassium thiocyanate Potassium salt, sodium chloride, sodium bromide, yo Sodium salts such as sodium chloride, sodium nitrate, sodium perchlorate and sodium thiocyanate, zinc salts such as zinc chloride, zinc bromide, zinc iodide, zinc nitrate, zinc perchlorate and zinc thiocyanate, Magnesium salts such as magnesium chloride, magnesium bromide, magnesium iodide, magnesium nitrate, magnesium
- the concentration of the inorganic salt can be 1.0% by mass or more, 5.0% by mass or more, 9.0% by mass or more, 15% by mass or more, or 20.0% by mass or more based on the total amount of protein. .
- the concentration of the inorganic salt may also be 40% by mass or less, 35% by mass or less, or 30% by mass or less based on the total amount of protein.
- the dispersion and the protein solution can contain various additives as necessary.
- the additive include a plasticizer, a crystal nucleating agent, an antioxidant, an ultraviolet absorber, a colorant, a filler, and a synthetic resin.
- the concentration of the additive may be 50% by mass or less based on the total amount of protein.
- a protein solution is produced by applying a predetermined pressure to a dispersion containing protein and a polar solvent and dissolving the protein in the polar solvent.
- pressure By applying pressure to the dispersion, it is possible to dissolve the protein in a polar solvent even at a relatively low temperature. Therefore, it is possible to produce a high-concentration solution while suppressing the induction of protein alteration, gelation, and degradation. Furthermore, since the concentration step using dialysis or the like is not necessarily required, the productivity of the protein solution can be increased.
- the pressure applied to the dispersion is adjusted so that the protein is appropriately dissolved in the polar solvent according to the type of protein and polar solvent, the desired concentration, and the like.
- the pressure applied to the dispersion is 0.05 MPa or more, 0.06 MPa or more, 0.07 MPa or more, 0.08 MPa or more, 0.1 MPa or more, 1.0 MPa or more, 5.0 MPa or more, or 10 MPa or more.
- the pressure applied to the dispersion can be 300 MPa or less, 150 MPa or less, 50 MPa or less, or 30 MPa or less.
- the method for applying pressure to the dispersion is not particularly limited. For example, by applying an inert gas such as nitrogen or argon, or air in a pressure vessel containing the dispersion and adjusting the pressure in the pressure vessel by heating or the like, the pressure can be applied to the dispersion. it can.
- an inert gas such as nitrogen or argon, or air in a pressure vessel containing the dispersion and adjusting the pressure in the pressure vessel by heating or the like
- the pressure may be applied to the dispersion while heating the dispersion.
- the heating is not limited to the time during which the pressure is applied.
- the pressure may be applied to the dispersion after heating the dispersion to a predetermined temperature.
- the heating temperature may be 150 ° C. or lower, 140 ° C. or lower, 135 ° C. or lower, or 130 ° C. or lower.
- the heating temperature is preferably 140 ° C. or lower from the viewpoint of further suppressing the degradation of the protein mediated by water. From the viewpoint of obtaining a higher concentration solution, the heating temperature may be 70 ° C. or higher, 90 ° C. or higher, or 100 ° C. or higher.
- the heating temperature may be 70 ° C. or higher and 150 ° C. or lower, 90 ° C. or higher and 140 ° C. or lower, or 100 ° C. or higher and 130 ° C. or lower.
- the heating temperature may be a constant temperature or may vary.
- the pressure may be applied to the dispersion while stirring the dispersion.
- Stirring is not limited to applying pressure, and the dispersion may be stirred before and after applying pressure.
- the stirring method is not particularly limited.
- the dispersion liquid can be agitated by an inclined blade, a turbine blade, or the like.
- the protein solution obtained after pressurization may contain pressurization gas. Therefore, the method for producing a protein solution according to one embodiment may further include removing gas from the protein solution.
- the method for removing the gas is not particularly limited, and examples thereof include a method using a centrifuge. By centrifuge the protein solution, it is possible to remove a layer containing a relatively large amount of gas.
- the protein obtained by the method of one embodiment can include a protein dissolved in a polar solvent at a high concentration.
- the concentration of protein dissolved in the polar solvent in the protein solution can be similar to the concentration in the dispersion. Specifically, the concentration of the protein dissolved in the polar solvent is 1% by mass or more, 15% by mass or more, 30% by mass or more, 40% by mass or more, or 50% by mass or more based on the mass of the protein solution. It can be 70% by weight or less, 65% by weight or less, or 60% by weight or less.
- the protein solution containing protein at a high concentration can be used, for example, to produce a protein compact by various methods.
- the method for producing a shaped body according to an embodiment may include removing a polar solvent from the protein solution to obtain a shaped body containing protein. According to this method, it is possible to reduce the amount of the solvent to be removed in the process of producing the molded body, so that the production cost can be reduced.
- a protein solution containing spider silk fibroin at a high concentration can be used to produce a molded article having excellent physical properties utilizing the characteristics of spider silk fibroin.
- a molded body such as a gel, a film or a fiber
- the film can be produced, for example, by a method of forming a protein solution (dope solution) film and removing the polar solvent from the formed film.
- the fiber can be produced, for example, by a method of spinning a protein solution and removing a polar solvent from the spun protein solution.
- the protein forming the compact can also be regenerated using the method for producing the protein solution described above.
- One embodiment of a method for regenerating a protein from a shaped body is a protein containing a protein and a polar solvent in which the protein is dissolved by applying pressure to a polar solvent in contact with the shaped body containing the protein. Obtaining a solution and recovering the protein from the protein solution can be included.
- the polar solvent used in the method for regenerating protein and materials that can be added thereto can be selected in the same manner as in the above-described method for producing a protein solution.
- the molded body may be immersed in a polar solvent, and pressure may be applied to the polar solvent.
- a compact formed by pulverization or the like may be dispersed in a polar solvent to prepare a dispersion, and pressure may be applied to the dispersion.
- Conditions such as pressure and heating can be set in the same manner as in the above-described method for producing a protein solution.
- the method for recovering the protein from the protein solution is not particularly limited, and a normal method such as a method for removing the polar solvent from the protein solution or reprecipitation can be applied.
- a protein in an arbitrary form such as powder may be recovered from the protein solution containing the protein eluted from the molded body, or the molded body may be directly produced by the method described above.
- ADF3Kai gene A partial amino acid sequence of ADF3 (NCBI accession number: AAC47010, GI: 1263287), which is one of the two main dragline proteins of the Nigori spider, was obtained from the NCBI web database, A gene encoding an amino acid sequence (SEQ ID NO: 5) comprising an initiation codon, a His10 tag and an HRV3C protease (Human rhinovirus 3C protease) recognition site (SEQ ID NO: 4) added to the N-terminus of the same sequence is synthesized by GenScript. Entrusted.
- a pUC57 vector (with an Nde I site immediately upstream of the 5 ′ end and an Xba I site immediately downstream of the 5 ′ end) into which the ADF3Kai gene consisting of the base sequence shown in SEQ ID NO: 6 had been introduced was obtained. Thereafter, the gene was treated with restriction enzymes with Nde I and EcoR I and recombined into a pET22b (+) expression vector.
- the pET22b (+) expression vector containing the ADF3Kai-noNR gene sequence obtained above was transformed into E. coli Rosetta (DE3). After culturing the obtained single colony in 2 mL of LB medium containing ampicillin for 15 hours, 1.4 mL of the same culture solution was added to 140 mL of LB medium containing ampicillin, and cultured at 37 ° C. and 200 rpm. The culture was continued until the OD600 was 3.5. Next, a culture solution having an OD600 of 3.5 was added to 7 L of 2 ⁇ YT medium containing ampicillin together with 140 mL of 50% glucose, and further cultured until the OD600 reached 4.0.
- IPTG isopropyl- ⁇ -thiogalactoviranoside
- the dissolved protein solution is centrifuged (11,000 ⁇ g, 10 minutes, room temperature) with the above-mentioned Tommy Seiko centrifuge, and the supernatant is used with a dialysis tube (Sanko Junyaku Co., Ltd. cellulose tube 36/32). And dialyzed against water.
- the white aggregated protein obtained after dialysis was recovered by centrifugation, the water was removed with a freeze dryer, and the lyophilized powder was recovered.
- the degree of purification of the target protein ADF3Kai-noNR in the obtained lyophilized powder was confirmed by image analysis of the results of polyacrylamide gel electrophoresis (CBB staining) of the powder using Totallab (nonlinear dynamics ltd.). As a result, the purity of ADF3Kai-noNR was about 85%.
- Table 1 shows the ratio of the lyophilized powder (molecular weight: 60 kDa) of spider silk polypeptide (spider silk fibroin) obtained in the above “Preparation Example of Spider Silk Polypeptide” and water or dimethyl sulfoxide (DMSO). (Part by mass) to prepare a dispersion in which the spider silk polypeptide is dispersed in water. As shown in Table 1, lithium chloride was added to some of the dispersions. The obtained dispersion was put in a pressure vessel, and the pressure vessel was sealed and heated so that the temperature in the vessel became 90 ° C.
- FIG. 1 and FIG. 2 are analysis results by SDS-PAGE of the protein solutions obtained in Example 4 and Example 5, respectively.
- “R” in the figure indicates a reference test using a sample prepared by immersing a lyophilized powder of a spider silk polypeptide in water and drying it. The remaining degree of spider silk polypeptide determined from the comparison of the intensity of color development was about 83% in Example 4 and about 100% in Example 5.
- (A) n motif ((A) 5 ) is deleted every two from the N-terminal side to the C-terminal side, and [(A) n motif-REP] is inserted before the C-terminal sequence.
- One is inserted and all GGX in REP is replaced with GQX.
- the amino acid sequence shown in SEQ ID NO: 13 is obtained by adding the amino acid sequence shown in SEQ ID NO: 14 (tag sequence and hinge sequence) to the N-terminus of the amino acid sequence shown in SEQ ID NO: 12.
- a nucleic acid encoding a protein having the amino acid sequence represented by SEQ ID NO: 13 with a His tag sequence and a hinge sequence (SEQ ID NO: 14) added to the N-terminus of the amino acid sequence represented by SEQ ID NO: 12 was synthesized.
- the nucleic acid was added with an NdeI site at the 5 'end and an EcoRI site downstream of the stop codon.
- the nucleic acid was cloned into a cloning vector (pUC118). Thereafter, the nucleic acid was cleaved by restriction enzyme treatment with NdeI and EcoRI, and then recombined with the protein expression vector pET-22b (+) to obtain an expression vector.
- the seed culture solution was added to a jar fermenter to which 500 ml of production medium (Table 4) was added so that the OD 600 was 0.05, and transformed E. coli was inoculated.
- the culture solution temperature was maintained at 37 ° C., and the culture was performed at a constant pH of 6.9. Further, the dissolved oxygen concentration in the culture solution was maintained at 20% of the dissolved oxygen saturation concentration.
- a feed solution (glucose 455 g / 1 L, Yeast Extract 120 g / 1 L) was added at a rate of 1 ml / min.
- the culture solution temperature was maintained at 37 ° C., and the culture was performed at a constant pH of 6.9.
- the dissolved oxygen concentration in the culture solution was maintained at 20% of the dissolved oxygen saturation concentration, and cultured for 20 hours.
- 1M isopropyl- ⁇ -thiogalactopyranoside (IPTG) was added to the culture solution to a final concentration of 1 mM to induce expression of the target protein.
- the culture solution was centrifuged, and the cells were collected. SDS-PAGE was performed using cells prepared from the culture solution before and after the addition of IPTG, and the expression of the target protein was confirmed by the appearance of a band of the desired protein size depending on the addition of IPTG.
- the washed precipitate is suspended in 8 M guanidine buffer (8 M guanidine hydrochloride, 10 mM sodium dihydrogen phosphate, 20 mM NaCl, 1 mM Tris-HCl, pH 7.0) to a concentration of 100 mg / mL, and 30 ° C. at 30 ° C. Stir with a stirrer for minutes to dissolve. After dissolution, dialysis was performed with water using a dialysis tube (cellulose tube 36/32 manufactured by Sanko Junyaku Co., Ltd.). The white aggregated protein obtained after dialysis was recovered by centrifugation, the water was removed with a freeze dryer, and the lyophilized powder was recovered.
- 8 M guanidine buffer 8 M guanidine hydrochloride, 10 mM sodium dihydrogen phosphate, 20 mM NaCl, 1 mM Tris-HCl, pH 7.0
- the degree of purification of the target protein in the obtained lyophilized powder was confirmed by image analysis of the result of polyacrylamide gel electrophoresis of the powder using Totallab (nonlinear dynamics ltd.). As a result, the degree of protein purification was about 85%.
- the obtained dispersion was put in a pressure vessel, sealed, and then intermittently heated so that the temperature in the vessel was maintained at a predetermined temperature of 90 to 100 ° C.
- the temperature in the container is raised to 90 to 100 ° C.
- the solvent in the dispersion is evaporated, the pressure in the container is increased, and a pressure (calculated value) of 0.08 to 0.1 MPa is applied to the dispersion.
- a pressure (calculated value) of 0.08 to 0.1 MPa is applied to the dispersion.
- the dissolution state of the polypeptide was visually observed, and the solubility was evaluated according to the following criteria. The results are shown in Table 5.
- B A slight amount of undissolved polypeptide was observed.
- C The polypeptide did not dissolve.
- FIG. 3 shows the analysis results of the protein solutions obtained in Examples 14 to 19 by SDS-PAGE. The results are shown in Table 5.
- “A” indicates that most of the structural proteins in the solution were not decomposed. In any of the examples, a protein solution was obtained while suppressing protein degradation.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Insects & Arthropods (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Manufacture Of Macromolecular Shaped Articles (AREA)
Abstract
Description
(1)ADF3Kaiの遺伝子の合成
ニワオニグモの2つの主要なしおり糸タンパク質の一つであるADF3の部分的なアミノ酸配列(NCBIアクセッション番号:AAC47010、GI:1263287)をNCBIのウェブデータベースより取得し、同配列のN末端に開始コドン及びHis10タグ及びHRV3Cプロテアーゼ(Human rhinovirus 3Cプロテアーゼ)認識サイトからなる(配列番号4)を付加したアミノ酸配列(配列番号5)、をコードする遺伝子を、GenScript社に合成委託した。その結果、配列番号6で示す塩基配列からなるADF3Kaiの遺伝子が導入されたpUC57ベクター(遺伝子の5’末端直上流にNde Iサイト、及び5’末端直下流にXba Iサイト有り)を取得した。その後、同遺伝子をNde I及びEcoR Iで制限酵素処理し、pET22b(+)発現ベクターに組み換えた。
上記で得られたADF3Kaiの遺伝子が導入されたpET22b(+)ベクターを鋳型に、PrimeStar Mutagenesis Basal Kit(タカラバイオ株式会社製)を用いた部位特異的変異導入により、ADF3Kaiのアミノ酸配列(配列番号5)における第543番目のアミノ酸残基バリン(Val)に対応するコドンGTGを終止コドンTAAに変異させ、配列番号11に示すADF3Kai-noNRの遺伝子をpET22b(+)上に構築した。変異の導入の正確性については、3130xl Genetic Analyzer(Applied Biosystems)を用いたシーケンス反応により確認した。なお、ADF3Kai-noNRのアミノ酸配列は配列番号7で示すとおりである。
上記で得られたADF3Kai-noNRの遺伝子配列を含むpET22b(+)発現ベクターを、大腸菌Rosetta(DE3)に形質転換した。得られたシングルコロニーを、アンピシリンを含む2mLのLB培地で15時間培養後、同培養液1.4mLを、アンピシリンを含む140mLのLB培地に添加し、37℃、200rpmの条件下で、培養液のOD600が3.5になるまで培養した。次に、OD600が3.5の培養液を、アンピシリンを含む7Lの2×YT培地に50%グルコース140mLと共に加え、OD600が4.0になるまでさらに培養した。その後、得られたOD600が4.0の培養液に、終濃度が0.5mMになるようにイソプロピル-β-チオガラクトビラノシド(IPTG)を添加してタンパク質発現を誘導した。IPTG添加後2時間経過した時点で、培養液を遠心分離し、菌体を回収した。IPTG添加前とIPTG添加後の培養液から調製したタンパク質溶液をポリアクリルアミドゲルに泳動させたところ、IPTG添加に依存して目的サイズのバンドが観察され、目的とするタンパク質が発現していることを確認した。ADF3Kai-noNRのタンパク質を発現している大腸菌を冷凍庫(-20℃)で保存した。
(I)遠沈管(50mL)に、ADF3Kai-noNRのタンパク質を発現している大腸菌の菌体約4.5gと、緩衝液AI(20mM Tris-HCl、pH7.4)30mLを添加し、ミキサー(GE社製「SI-0286」、レベル10)で菌体を分散させた後、遠心分離機(トミー精工製の「MX-305」)で遠心分離(10,000rpm、10分、室温)し、上清を捨てた。
(II)遠心分離で得られた沈殿物(菌体)に緩衝液AIを30mLと、0.1MのPMSF(イソプロパノールで溶解)を0.3mL添加し、上記GE社製のミキサー(レベル10)で3分間分散させた。その後、超音波破砕機(SONIC&MATERIALSINC製「VCX500」)を用いて菌体を破砕し、遠心分離(10,000rpm、10分、室温)した。
(III)遠心分離で得られた沈殿物に緩衝液AIを30mL加え、ミキサー(IKA社製「T18ベーシック ウルトラタラックス」、レベル2)で3分間分散させた後、上記トミー精工製の遠心分離機で遠心分離(10,000rpm、10分、室温)し、上清を除去した。
(IV)上清を捨てた遠沈管に7.5Mの尿素緩衝液I(7.5M尿素、10mM リン酸二水素ナトリウム、20mM NaCl、1mM Tris-HCl、pH7.0)を加え、上記SMT社製の超音波破砕機(レベル7)で沈殿を良く分散させた。その後、上記タイテック社製のシェイカー(200rpm、60℃)で120分間溶解させた。溶解後のタンパク質溶液を上記トミー精工製の遠心分離機で遠心分離(11,000×g、10分、室温)し、上清を透析チューブ(三光純薬株式会社セルロースチューブ36/32)を用いて水で透析を行った。透析後に得られた白色の凝集タンパク質を遠心分離により回収し、凍結乾燥機で水分をのぞき、凍結乾燥粉末を回収した。得られた凍結乾燥粉末における目的タンパク質ADF3Kai-noNRの精製度は、粉末のポリアクリルアミドゲル電気泳動(CBB染色)の結果をTotallab(nonlinear dynamics ltd.)を用いて画像解析することにより確認した。その結果、ADF3Kai-noNRの精製度は約85%であった。
<クモ糸ポリペプチドの溶解試験>
上記「クモ糸ポリペプチドの調製例」で得られた、クモ糸ポリペプチド(クモ糸フィブロイン)の凍結乾燥粉末(分子量:60kDa)と、水又はジメチルスルホキシド(DMSO)とを表1に示す割合(質量部)で混合して、クモ糸ポリペプチドが水中に分散している分散液を調製した。表1に示すように、一部の分散液には塩化リチウムを加えた。得られた分散液を耐圧容器に入れ、耐圧容器を、密閉してから容器内温度が90℃になるように加熱した。さらに耐圧容器内に窒素を導入して、容器内の圧力が1.0~10MPaの所定の圧力となるように調整し、分散液に圧力を印加した。2時間経過したところで加圧を中止し、耐圧容器を25℃まで冷却した。その後、ポリペプチドの溶解の状態を目視で観察し、下記基準に従って溶解性を評価した。結果を表1に示す。
A:ポリペプチドがすべて溶解した。
B:ポリペプチドの溶け残りがわずかに観察された。
C:ポリペプチドが溶けなかった。
クモ糸ポリペプチドの溶解が確認された溶液について、ドデシル硫酸ナトリウム(SDS)を用いたSDS-PAGEによる分析を行った。電気泳動の結果を下記条件で画像解析することにより、溶解したポリペプチドの分解の状態を確認した。結果を表1に示す。表1中、「A」は溶液中の大部分の構造タンパク質が分解していなかったことを示し、「C」は溶液中の大部分の構造タンパク質が分解していたことを示す。
電源装置:PowerPactm Universal(BIO-RAD製)
画像解析システム:Gel Doctm EZ Imager(BIO-RAD製)
泳動用ゲル:Mini-PROTEAN(R) TGXTM Gels(BIO-RAD製)
分子量マーカー:XL-Ladder(APRO SCOEMCE製)
固定液:NovexTM InVisionTM His-Tag In-Gel Staining Kit(Thermo Fisher Scientific製)
染色剤:OrioleTM Fluorescent Gel Stain(BIO-RAD製)
<絹フィブロインの溶解試験>
Bombyx mori由来の絹フィブロイン(fibroin heavy chain Fib-H[Bombyx mori]、Accession No.AAF76983。以下、単に「絹フィブロイン」ともいう。理論分子量:391.5kDa)と、水とを表2に示す割合(質量部)で混合して、絹フィブロインが水中に分散している分散液を調製した。表2に示すように、一部の分散液には塩化リチウムを加えた。得られた分散液を耐圧容器に入れ、耐圧容器を、密閉してから容器内温度が90℃になるように加熱した。さらに耐圧容器内に窒素を導入して、容器内の圧力が1.0~10MPaの所定の圧力となるように調整し、分散液を加圧した。48時間経過したところで加圧を中止し、耐圧容器を25℃まで冷却した。その後、絹フィブロインの溶解の状態を目視で観察し、クモ糸フィブロインと同様の基準にて溶解性を評価した。結果を表2に示す。絹フィブロインは分子量が大きいため、SDS-PAGEによる分析が困難であった。
<クモ糸ポリペプチドの溶解試験2>
(1)改変フィブロインをコードする核酸の合成、及び発現ベクターの構築
天然由来のクモ糸フィブロインであるNephila clavipes(GenBankアクセッション番号:P46804.1、GI:1174415)の塩基配列及びアミノ酸配列に基づき、配列番号12及び13でそれぞれ示されるアミノ酸配列を有する改変フィブロインを設計した。
配列番号12で示されるアミノ酸配列は、上記天然由来のフィブロインから出発して、その(A)nモチーフ中のアラニン残基が連続するアミノ酸配列をアラニン残基が連続する数が5つになるよう欠失させ、N末端側からC末端側に向かって2つおきに(A)nモチーフ((A)5)を欠失させ、C末端配列の手前に[(A)nモチーフ-REP]を1つ挿入し、REP中の全てのGGXをGQXに置換したものである。配列番号13で示されるアミノ酸配列はこの配列番号12で示されるアミノ酸配列のN末端に配列番号14で示されるアミノ酸配列(タグ配列及びヒンジ配列)を付加したものである。
配列番号13で示されるアミノ酸配列を有するタンパク質をコードする核酸を含むpET22b(+)発現ベクターで、大腸菌BLR(DE3)を形質転換した。当該形質転換大腸菌を、アンピシリンを含む2mLのLB培地で15時間培養した。同培養液をアンピシリンを含む100mLのシード培養用培地(表3)にOD600が0.005となるように添加して、形質転換大腸菌を植菌した。培養液温度を30℃に保ち、OD600が5になるまでフラスコ培養を行い(約15時間)、シード培養液を得た。
IPTGを添加してから2時間後に回収した菌体を20mM Tris-HCl buffer(pH7.4)で洗浄した。洗浄後の菌体を約1mMのPMSFを含む20mMTris-HCl緩衝液(pH7.4)に懸濁させ、高圧ホモジナイザー(GEA Niro Soavi社)で細胞を破砕した。破砕した細胞を遠心分離し、沈殿物を得た。得られた沈殿物を、高純度になるまで20mMTris-HCl緩衝液(pH7.4)で洗浄した。洗浄後の沈殿物を100mg/mLの濃度になるように8M グアニジン緩衝液(8Mグアニジン塩酸塩、10mMリン酸二水素ナトリウム、20mMNaCl、1mMTris-HCl、pH7.0)で懸濁し、60℃で30分間、スターラーで撹拌し、溶解させた。溶解後、透析チューブ(三光純薬株式会社製のセルロースチューブ36/32)を用いて水で透析を行った。透析後に得られた白色の凝集タンパク質を遠心分離により回収し、凍結乾燥機で水分を除き、凍結乾燥粉末を回収した。
上記で得られた、クモ糸ポリペプチド(クモ糸フィブロイン)の凍結乾燥粉末(分子量:50kDa)と、水、エタノール、プロパノール、ブタノール又はクリンソルブP-7(エタノール85.5±1.0%、イソプロパノール5.0%未満、ノルマルプロパノール9.6±0.5%、及び水分0.2%以下を含有する混合溶媒、「クリンソルブ」は日本アルコール販売株式会社の登録商標である。)とを、表5に示す割合(質量部)で混合して、クモ糸ポリペプチドが液中に分散している分散液を調製した。得られた分散液を耐圧容器に入れ、密閉してから容器内温度が90~100℃の所定の温度に保持されるように断続的に加熱した。容器内温度を90~100℃まで上げることで分散液中の溶媒が蒸発し、容器内の圧力が上昇して分散液に0.08~0.1MPaの圧力(計算値)が印加される。加熱を開始してから25分間容器内温度を90~100℃に保持したのち、ポリペプチドの溶解の状態を目視で観察し、下記基準に従って溶解性を評価した。結果を表5に示す。
A:ポリペプチドがすべて溶解した。
B:ポリペプチドの溶け残りがわずかに観察された。
C:ポリペプチドが溶けなかった。
クモ糸ポリペプチドの溶解が確認された溶液について、実施例1~7と同様の条件のSDS-PAGEによる分析を行い、溶解したポリペプチドの分解の状態を確認した。図3は、実施例14~19で得られたタンパク質溶液のSDS-PAGEによる分析結果である。結果を表5に示す。表5中、「A」は溶液中の大部分の構造タンパク質が分解していなかったことを示す。いずれの実施例においても、タンパク質の分解を抑制しながらタンパク質溶液が得られた。
Claims (16)
- タンパク質と該タンパク質が分散している極性溶媒とを含有する分散液に圧力を印加して、前記タンパク質と該タンパク質が溶解している前記極性溶媒とを含有するタンパク質溶液を得ることを含む、
タンパク質溶液を製造する方法。 - 前記圧力が、0.05MPa以上である、請求項1に記載の方法。
- 前記タンパク質が構造タンパク質である、請求項1又は2に記載の方法。
- 前記構造タンパク質が、フィブロイン、及びケラチンからなる群より選択される1種以上の構造タンパク質である、請求項3に記載の方法。
- 前記構造タンパク質が、絹フィブロイン、クモ糸フィブロイン、及びホーネットシルクフィブロインからなる群より選択される1種以上のフィブロインである、請求項3に記載の方法。
- 前記分散液を加熱しながら前記分散液に前記圧力が印加される、請求項1~5のいずれか一項に記載の方法。
- 前記極性溶媒が、水、アルコール、ジメチルスルホキシド、ジメチルホルムアミド、及びヘキサフルオロアセトンからなる群より選択される1種以上の溶媒を含む、請求項1~6のいずれか一項に記載の方法。
- クモ糸フィブロインと、該クモ糸フィブロインが溶解している極性溶媒と、を含有するタンパク質溶液であって、
前記極性溶媒に溶解している前記クモ糸フィブロインの濃度が、当該タンパク質溶液の質量を基準として1~70質量%である、タンパク質溶液。 - 請求項1~7のいずれか一項に記載の方法により、タンパク質と該タンパク質が溶解している極性溶媒とを含有するタンパク質溶液を得ることと、
前記タンパク質溶液から前記極性溶媒を除去して、前記タンパク質を含有する成形体を得ることと、
を含む、成形体を製造する方法。 - タンパク質を含有する成形体に接触している極性溶媒に圧力を印加して、前記タンパク質と該タンパク質が溶解している前記極性溶媒とを含有するタンパク質溶液を得ることと、
前記タンパク質溶液から前記タンパク質を回収することと、
を含む、
成形体からタンパク質を再生する方法。 - 前記圧力が、0.05MPa以上である、請求項10に記載の方法。
- 前記タンパク質が構造タンパク質である、請求項10又は11に記載の方法。
- 前記構造タンパク質が、フィブロイン、及びケラチンからなる群より選択される1種以上の構造タンパク質である、請求項12に記載の方法。
- 前記構造タンパク質が、絹フィブロイン、クモ糸フィブロイン、及びホーネットシルクフィブロインからなる群より選択される1種以上のフィブロインである、請求項12に記載の方法。
- 前記極性溶媒を加熱しながら前記極性溶媒に前記圧力が印加される、請求項10~14のいずれか一項に記載の方法。
- 前記極性溶媒が、水、アルコール、ジメチルスルホキシド、ジメチルホルムアミド、及びヘキサフルオロアセトンからなる群より選択される1種以上の溶媒を含む、請求項10~15のいずれか一項に記載の方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/780,477 US20180355120A1 (en) | 2015-12-01 | 2016-11-29 | Method for Producing Protein Solution |
EP16870659.6A EP3385305A4 (en) | 2015-12-01 | 2016-11-29 | PROCESS FOR PRODUCING A PROTEIN SOLUTION |
CN201680070357.4A CN108368271A (zh) | 2015-12-01 | 2016-11-29 | 制造蛋白质溶液的方法 |
JP2017554111A JPWO2017094722A1 (ja) | 2015-12-01 | 2016-11-29 | タンパク質溶液を製造する方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-235079 | 2015-12-01 | ||
JP2015235079 | 2015-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017094722A1 true WO2017094722A1 (ja) | 2017-06-08 |
Family
ID=58796987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/085409 WO2017094722A1 (ja) | 2015-12-01 | 2016-11-29 | タンパク質溶液を製造する方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20180355120A1 (ja) |
EP (1) | EP3385305A4 (ja) |
JP (1) | JPWO2017094722A1 (ja) |
CN (1) | CN108368271A (ja) |
WO (1) | WO2017094722A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018123953A1 (ja) * | 2016-12-27 | 2018-07-05 | Spiber株式会社 | タンパク質の回収方法 |
WO2018235958A1 (ja) * | 2017-06-23 | 2018-12-27 | Spiber株式会社 | タンパク質の精製方法、タンパク質溶液の製造方法、及びタンパク質成形体の製造方法 |
JP2019151834A (ja) * | 2018-02-28 | 2019-09-12 | セントラル硝子株式会社 | タンパク質溶液の調製方法およびそれを用いた分子量測定方法 |
JP2019172985A (ja) * | 2018-03-26 | 2019-10-10 | セントラル硝子株式会社 | シルクフィブロイン溶液の製造方法およびそれから形成される成形体の製造方法 |
WO2020054873A1 (ja) * | 2018-09-14 | 2020-03-19 | Spiber株式会社 | フィブロイン溶液を製造する方法、及びタンパク質成形体を製造する方法 |
WO2021035184A1 (en) | 2019-08-22 | 2021-02-25 | Bolt Threads, Inc. | Methods for improved extraction of spider silk proteins |
JP7458619B2 (ja) | 2019-01-31 | 2024-04-01 | Spiber株式会社 | フィブロイン繊維の製造方法及びフィブロイン溶液 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109778343B (zh) * | 2019-01-14 | 2021-08-06 | 青岛金氧牧服饰有限公司 | 一种透气抗菌共混蛋白纤维及其织物的制备方法和应用 |
US20220235099A1 (en) * | 2019-05-29 | 2022-07-28 | Spiber Inc. | Structural Protein Microbody and Method for Producing Same, Method for Producing Nanofiber, and Method for Producing Protein Structure |
AU2020349480A1 (en) * | 2019-09-16 | 2022-03-03 | Bolt Threads, Inc. | Methods for isolating spider silk proteins via high shear solubilization |
EP4039858A4 (en) * | 2019-09-30 | 2023-11-01 | Spiber Inc. | METHOD FOR MANUFACTURING A MOLDED PROTEIN BODY |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004530651A (ja) * | 2000-10-31 | 2004-10-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド, ア ボディー コーポレイト | 高圧を使用する、改善されたタンパク質脱凝集およびリフォールディング |
US20110070219A1 (en) * | 2009-04-27 | 2011-03-24 | Seefeldt Matthew B | High pressure protein crystallization |
WO2015042164A2 (en) * | 2013-09-17 | 2015-03-26 | Refactored Materials, Inc. | Methods and compositions for synthesizing improved silk fibers |
JP2015205462A (ja) * | 2014-04-21 | 2015-11-19 | 日立化成株式会社 | フィブロイン複合体 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH673117A5 (ja) * | 1986-12-10 | 1990-02-15 | Ajinomoto Kk | |
US9428648B2 (en) * | 2010-12-03 | 2016-08-30 | Green Materials, Llc | Wheat gluten based compositions and articles made therefrom |
US20140193466A1 (en) * | 2011-06-07 | 2014-07-10 | Cornell University | Silk compositions and methods of using same |
WO2013065651A1 (ja) * | 2011-11-02 | 2013-05-10 | スパイバー株式会社 | タンパク質溶液及びこれを用いたタンパク質繊維の製造方法 |
FR2995214B1 (fr) * | 2012-09-10 | 2014-11-21 | Adocia | Solution a viscosite reduite de proteine a concentration elevee |
-
2016
- 2016-11-29 JP JP2017554111A patent/JPWO2017094722A1/ja active Pending
- 2016-11-29 WO PCT/JP2016/085409 patent/WO2017094722A1/ja active Application Filing
- 2016-11-29 US US15/780,477 patent/US20180355120A1/en not_active Abandoned
- 2016-11-29 CN CN201680070357.4A patent/CN108368271A/zh active Pending
- 2016-11-29 EP EP16870659.6A patent/EP3385305A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004530651A (ja) * | 2000-10-31 | 2004-10-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド, ア ボディー コーポレイト | 高圧を使用する、改善されたタンパク質脱凝集およびリフォールディング |
US20110070219A1 (en) * | 2009-04-27 | 2011-03-24 | Seefeldt Matthew B | High pressure protein crystallization |
WO2015042164A2 (en) * | 2013-09-17 | 2015-03-26 | Refactored Materials, Inc. | Methods and compositions for synthesizing improved silk fibers |
JP2015205462A (ja) * | 2014-04-21 | 2015-11-19 | 日立化成株式会社 | フィブロイン複合体 |
Non-Patent Citations (2)
Title |
---|
See also references of EP3385305A4 * |
WEINMANN W; ET AL: "Isolation of hydrophobic lipoproteins in organic solvents by pressure-assisted capillary electrophoresis for subsequent mass spectrometric characterization.", JOURNAL OF CHROMATOGRAPHY A, vol. 664, no. 2, 1994, pages 271 - 275, XP008039556 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018123953A1 (ja) * | 2016-12-27 | 2018-07-05 | Spiber株式会社 | タンパク質の回収方法 |
EP3564254A4 (en) * | 2016-12-27 | 2020-10-21 | Spiber Inc. | PROTEIN RECOVERY PROCESS |
WO2018235958A1 (ja) * | 2017-06-23 | 2018-12-27 | Spiber株式会社 | タンパク質の精製方法、タンパク質溶液の製造方法、及びタンパク質成形体の製造方法 |
JP2019151834A (ja) * | 2018-02-28 | 2019-09-12 | セントラル硝子株式会社 | タンパク質溶液の調製方法およびそれを用いた分子量測定方法 |
JP7323766B2 (ja) | 2018-02-28 | 2023-08-09 | セントラル硝子株式会社 | タンパク質溶液の調製方法およびそれを用いた分子量測定方法 |
JP2019172985A (ja) * | 2018-03-26 | 2019-10-10 | セントラル硝子株式会社 | シルクフィブロイン溶液の製造方法およびそれから形成される成形体の製造方法 |
JP7284384B2 (ja) | 2018-03-26 | 2023-05-31 | セントラル硝子株式会社 | シルクフィブロイン溶液の製造方法およびそれから形成される成形体の製造方法 |
WO2020054873A1 (ja) * | 2018-09-14 | 2020-03-19 | Spiber株式会社 | フィブロイン溶液を製造する方法、及びタンパク質成形体を製造する方法 |
JPWO2020054873A1 (ja) * | 2018-09-14 | 2021-08-30 | Spiber株式会社 | フィブロイン溶液を製造する方法、及びタンパク質成形体を製造する方法 |
JP7458619B2 (ja) | 2019-01-31 | 2024-04-01 | Spiber株式会社 | フィブロイン繊維の製造方法及びフィブロイン溶液 |
WO2021035184A1 (en) | 2019-08-22 | 2021-02-25 | Bolt Threads, Inc. | Methods for improved extraction of spider silk proteins |
EP4017865A4 (en) * | 2019-08-22 | 2023-08-23 | Bolt Threads, Inc. | PROCESS FOR IMPROVED EXTRACTION OF SPIDER SILK PROTEINS |
Also Published As
Publication number | Publication date |
---|---|
CN108368271A (zh) | 2018-08-03 |
EP3385305A4 (en) | 2019-11-13 |
JPWO2017094722A1 (ja) | 2018-10-11 |
EP3385305A1 (en) | 2018-10-10 |
US20180355120A1 (en) | 2018-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017094722A1 (ja) | タンパク質溶液を製造する方法 | |
JP7088511B2 (ja) | フィブロイン様タンパク質を含むコンポジット成形組成物及びその製造方法 | |
JP6959482B2 (ja) | 成形体及びその製造方法、並びに成形体のタフネスを向上させる方法 | |
US11174572B2 (en) | Composite molding composition including fibroin-like protein, and method for producing composite molding composition | |
WO2013065651A1 (ja) | タンパク質溶液及びこれを用いたタンパク質繊維の製造方法 | |
JP7436065B2 (ja) | タンパク質の回収方法 | |
WO2018043698A1 (ja) | モールド成形体及びモールド成形体の製造方法 | |
WO2014175177A1 (ja) | ポリペプチドヒドロゲル及びその製造方法 | |
JP6856828B2 (ja) | 極性溶媒溶液及びその製造方法 | |
WO2019151435A1 (ja) | カーボンナノチューブ分散剤、カーボンナノチューブ分散液、及びカーボンナノチューブの分散方法 | |
WO2018164195A1 (ja) | 精製されたタンパク質を製造する方法 | |
JPWO2018221498A1 (ja) | タンパク質繊維の製造方法 | |
WO2020067548A1 (ja) | 難燃性タンパク質成形体及びその製造方法 | |
JP7270978B2 (ja) | ポリペプチド溶液、及びポリペプチド繊維の製造方法、並びに人造ポリペプチド | |
WO2018216779A1 (ja) | ポリペプチド溶液及びこれを製造する方法、並びにポリペプチド成形体を製造する方法 | |
JP6810309B2 (ja) | 極性溶媒溶液及びその製造方法 | |
WO2017131195A1 (ja) | 成形体及びその製造方法、並びに成形体の結晶化度を向上させる方法 | |
WO2018163758A1 (ja) | モールド成形体及びモールド成形体の製造方法 | |
WO2019194231A1 (ja) | タンパク質組成物及びその製造方法 | |
JP7345155B2 (ja) | 保温性付与剤、及び物品に保温性を付与する方法 | |
WO2019189802A1 (ja) | 組換え構造タンパク質の製造方法、組換え構造タンパク質、タンパク質成形体及びタンパク質成形体の製造方法 | |
JP2019183300A (ja) | 成形体及び成形体の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16870659 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017554111 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016870659 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016870659 Country of ref document: EP Effective date: 20180702 |